Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vivesto ABOASMY 26 EV-to-OCF is 0.55 as of Aug. 18, 2026. GuruFocus rates OASMY with a GF Score™ of 26/100. The stock has 1 warning sign investors should review. Among 1,005 Drug Manufacturers companies, Vivesto AB ranks better than 75.22% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Vivesto AB's Enterprise Value is $-1.90 Mil.
Vivesto AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-3.43 Mil. Therefore, Vivesto AB's EV-to-OCF for today is 0.55.
The historical rank and industry rank for Vivesto AB's EV-to-OCF or its related term are showing as below:
OASMY'
s EV-to-OCF Range Over the Past 10 Years
Min: -446.34 Med: -3.85 Max: 491.72
Current: -3.41
During the past 13 years, the highest EV-to-OCF of Vivesto AB was 491.72. The lowest was -446.34. And the median was -3.85.
OASMY's EV-to-OCF is ranked better than 75.22% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 11.01
vs OASMY: -3.41
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vivesto AB's share price for today is $0.0001.
Vivesto AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.014.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Vivesto AB EV-to-OCF Related Terms
Vivesto AB EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Vivesto AB's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vivesto AB's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vivesto AB EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vivesto AB's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Vivesto AB's EV-to-OCF falls into.
Vivesto AB's current Enterprise Value is $-1.90 Mil.
Vivesto AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.43 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vivesto AB (OASMY) has a EV-to-OCF of 0.55 as of Aug. 18, 2026. According to the industry distribution chart, Vivesto AB ranks #249 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 24.8%.
Is Vivesto AB's EV-to-OCF too high?
Vivesto AB's current EV-to-OCF is 0.55. The Drug Manufacturers industry median EV-to-OCF is 11.01. Vivesto AB's value of 0.55 is 95% below this industry median. Based on the distribution chart, Vivesto AB ranks #249 out of 1005 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Vivesto AB has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Vivesto AB's EV-to-OCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vivesto AB ranks #249 out of 1005 companies for EV-to-OCF. This places Vivesto AB in the top 25% of its industry — outperforming the majority of peers. The industry median EV-to-OCF is 11.01. Vivesto AB's value of 0.55 is 95% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 11.01, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vivesto AB's current EV-to-OCF of 0.55 is 95% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 11.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vivesto AB's current EV-to-OCF is 0.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivesto AB stock overvalued right now?
Vivesto AB (OASMY) has a current EV-to-OCF of 0.55. The current EV-to-OCF is 0.55 and 95% below the Drug Manufacturers industry median of 11.01. Vivesto AB's overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Vivesto AB (OASMY), the current EV-to-OCF is 0.55 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vivesto AB is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company's product development leverages its proprietary technology platforms to manufacture novel drug formulations that are intended to demonstrate improved properties in comparison with current alternatives, which can lead to a reduced side-effect profile and an expanded therapeutic area. The company has a portfolio of projects targeting cancer treatments.
26GF Score
Get the complete analysis for OASMY
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OASMY has been successfully added to your 
